

Scott M Grundy

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8596839/scott-m-grundy-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

198
papers

76,724
citations

100
h-index

230
g-index

230
ext. papers

87,418
ext. citations

9.7
avg, IF

7.97
L-index

#	Paper	IF	Citations
198	Managing Atherosclerotic Cardiovascular Risk in Young Adults: JACC State-of-the-Art Review.. <i>Journal of the American College of Cardiology</i> , 2022 , 79, 819-836	15.1	3
197	Utility of metabolic syndrome as a risk enhancing factor in decision of statin use. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 255-265	4.9	1
196	Chronic kidney disease and statin eligibility. <i>Journal of Clinical Lipidology</i> , 2021 , 15, 173-180	4.9	1
195	Department of Veterans Affairs (VA) and U.S. Department of Defense (DoD) guidelines for management of dyslipidemia and cardiovascular disease risk reduction: Putting evidence in context. <i>Progress in Cardiovascular Diseases</i> , 2021 , 68, 2-6	8.5	0
194	Coronary Artery Calcium: Where Do We Stand After Over 3 Decades?. <i>American Journal of Medicine</i> , 2021 , 134, 1091-1095	2.4	1
193	High-Intensity Statins Benefit High-Risk Patients: Why and How to Do Better. <i>Mayo Clinic Proceedings</i> , 2021 , 96, 2660-2670	6.4	1
192	Global Burden of Cardiovascular Diseases and Risk Factors, 1990-2019: Update From the GBD 2019 Study. <i>Journal of the American College of Cardiology</i> , 2020 , 76, 2982-3021	15.1	922
191	Temporal decline in non-high-density lipoprotein cholesterol in subjects with diabetes mellitus without atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2020 , 14, 425-430	4.9	1
190	The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guidelines on the Management of Blood Cholesterol in Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1673-1678	14.6	14
189	2018 American Heart Association/American College of Cardiology/Multisociety Guideline on the Management of Blood Cholesterol-Secondary Prevention. <i>JAMA Cardiology</i> , 2019 , 4, 589-591	16.2	21
188	Four Cases of Cholesterol Management Informed by the 2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol. <i>JAMA Cardiology</i> , 2019 , 4, 473-477	16.2	1
187	2018 American Heart Association/American College of Cardiology Multisociety Guideline on the Management of Blood Cholesterol: Primary Prevention. <i>JAMA Cardiology</i> , 2019 , 4, 488-489	16.2	12
186	Treating Hypercholesterolemia in Older Adults. <i>JAMA - Journal of the American Medical Association</i> , 2019 , 322, 695	27.4	1
185	Very High-Risk ASCVD and Eligibility for Nonstatin Therapies Based on the 2018 AHA/ACC Cholesterol Guidelines. <i>Journal of the American College of Cardiology</i> , 2019 , 74, 712-714	15.1	10
184	Current trends in non-HDL cholesterol and LDL cholesterol levels in adults with atherosclerotic cardiovascular disease. <i>Journal of Clinical Lipidology</i> , 2019 , 13, 563-567	4.9	10
183	2018 Cholesterol Clinical Practice Guidelines: Synopsis of the 2018 American Heart Association/American College of Cardiology/Multisociety Cholesterol Guideline. <i>Annals of Internal Medicine</i> , 2019 , 170, 779-783	8	27
182	The 2018 AHA/ACC/Multi-Society Cholesterol guidelines: Looking at past, present and future. <i>Progress in Cardiovascular Diseases</i> , 2019 , 62, 375-383	8.5	15

181	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2019 , 73, e285-e350	15.1	895
180	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Circulation</i> , 2019 , 139, e1082-e1143	16.7	836
179	2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. <i>Journal of the American College of Cardiology</i> , 2019 , 73, 3168-3209	15.1	654
178	Upper body fat predicts metabolic syndrome similarly in men and women. <i>European Journal of Clinical Investigation</i> , 2018 , 48, e12941	4.6	14
177	Long-Term Association of Low-Density Lipoprotein Cholesterol With Cardiovascular Mortality in Individuals at Low 10-Year Risk of Atherosclerotic Cardiovascular Disease. <i>Circulation</i> , 2018 , 138, 2315-2325	16.7	75
176	An Analysis of Individual Body Fat Depots and Risk of Developing Cancer: Insights From the Dallas Heart Study. <i>Mayo Clinic Proceedings</i> , 2017 , 92, 536-543	6.4	8
175	Metabolic Concomitants of Obese and Nonobese Women With Features of Polycystic Ovarian Syndrome. <i>Journal of the Endocrine Society</i> , 2017 , 1, 1417-1427	0.4	16
174	Overnutrition, ectopic lipid and the metabolic syndrome. <i>Journal of Investigative Medicine</i> , 2016 , 64, 1082-6	6	48
173	Association of triglyceride-to-high density lipoprotein cholesterol ratio to cardiorespiratory fitness in men. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 1414-1422.e1	4.9	7
172	Does Dietary Cholesterol Matter?. <i>Current Atherosclerosis Reports</i> , 2016 , 18, 68	6	31
171	Dyslipidaemia in 2015: Advances in treatment of dyslipidaemia. <i>Nature Reviews Cardiology</i> , 2016 , 13, 74-5	14.8	7
170	Metabolic syndrome update. <i>Trends in Cardiovascular Medicine</i> , 2016 , 26, 364-73	6.9	378
169	Scavenger Receptor B-1 Emerges as Anti-atherogenic Candidate. <i>Cell Metabolism</i> , 2016 , 23, 755-7	24.6	5
168	Fatty acid oxidation in normotriglyceridemic men. <i>Journal of Clinical Lipidology</i> , 2016 , 10, 283-8	4.9	6
167	Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2016 , 316, 1289-97	27.4	614
166	National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. <i>Journal of Clinical Lipidology</i> , 2015 , 9, 129-69	4.9	478
165	Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1828-1836	15.1	36
164	Perspectives on Cholesterol Guidelines. <i>Contemporary Endocrinology</i> , 2015 , 313-327	0.3	

163	The CardioMetabolic Health Alliance: Working Toward a New Care Model for the Metabolic Syndrome. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 1050-67	15.1	158
162	Adipose tissue and metabolic syndrome: too much, too little or neither. <i>European Journal of Clinical Investigation</i> , 2015 , 45, 1209-17	4.6	100
161	Is There a Gradient of Mortality Risk among Men with Low Cardiorespiratory Fitness?. <i>Medicine and Science in Sports and Exercise</i> , 2015 , 47, 1825-32	1.2	11
160	National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. <i>Journal of Clinical Lipidology</i> , 2015 , 9, S1-122.e1	4.9	293
159	Reply: Statin dose based on limited evidence. <i>Journal of the American College of Cardiology</i> , 2015 , 65, 760-1	15.1	2
158	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia--full report. <i>Journal of Clinical Lipidology</i> , 2014 , 8, 29-60	4.9	246
157	Ethnic and gender susceptibility to metabolic risk. <i>Metabolic Syndrome and Related Disorders</i> , 2014 , 12, 110-6	2.6	11
156	Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 485-94	15.1	372
155	2013 ACC/AHA guideline recommends fixed-dose strategies instead of targeted goals to lower blood cholesterol. <i>Journal of the American College of Cardiology</i> , 2014 , 64, 601-12	15.1	50
154	An assessment by the Statin Intolerance Panel: 2014 update. <i>Journal of Clinical Lipidology</i> , 2014 , 8, S72-81.9	4.9	107
153	Prediction of cardiovascular events in statin-treated stable coronary patients of the treating to new targets randomized controlled trial by lipid and non-lipid biomarkers. <i>PLoS ONE</i> , 2014 , 9, e114519	3.7	34
152	Statins: definitive translational research. <i>Molecular Medicine</i> , 2014 , 20 Suppl 1, S20-3	6.2	5
151	Cholesterol management in older persons. <i>American Journal of Medicine</i> , 2014 , 127, 1140-1	2.4	6
150	An International Atherosclerosis Society Position Paper: global recommendations for the management of dyslipidemia. <i>Journal of Clinical Lipidology</i> , 2013 , 7, 561-5	4.9	94
149	Plasma noncholesterol sterols as indicators of cholesterol absorption. <i>Journal of Lipid Research</i> , 2013 , 54, 873-5	6.3	10
148	Associations of visceral and abdominal subcutaneous adipose tissue with markers of cardiac and metabolic risk in obese adults. <i>Obesity</i> , 2013 , 21, E439-47	8	263
147	Metabolic risk susceptibility in men is partially related to adiponectin/leptin ratio. <i>Journal of Obesity</i> , 2013 , 2013, 409679	3.7	58
146	Waist circumference as measure of abdominal fat compartments. <i>Journal of Obesity</i> , 2013 , 2013, 454285.7	3.7	44

145	Influence of upper and lower body adipose tissue on insulin sensitivity in South Asian men. <i>Journal of Investigative Medicine</i> , 2012 , 60, 999-1004	2.9	15
144	Pre-diabetes, metabolic syndrome, and cardiovascular risk. <i>Journal of the American College of Cardiology</i> , 2012 , 59, 635-43	15.1	386
143	Treatment targets in the management of dyslipidemias: which targets in whom?. <i>Current Cardiology Reports</i> , 2012 , 14, 692-700	4.2	3
142	Cardiorespiratory fitness and metabolic risk. <i>American Journal of Cardiology</i> , 2012 , 109, 988-93	3	51
141	Cardiorespiratory fitness, LDL cholesterol, and CHD mortality in men. <i>Medicine and Science in Sports and Exercise</i> , 2012 , 44, 2132-7	1.2	22
140	Dysfunctional adiposity and the risk of prediabetes and type 2 diabetes in obese adults. <i>JAMA - Journal of the American Medical Association</i> , 2012 , 308, 1150-9	27.4	385
139	AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. <i>Journal of the American College of Cardiology</i> , 2011 , Clinical characteristics, vascular function, and inflammation in women with angina in the absence of coronary atherosclerosis: the Dallas Heart Study. <i>JACC: Cardiovascular Imaging</i> , 2011 , 4, 65-73	15.1	574
138	Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial). <i>American Journal of Cardiology</i> , 2011 , 108, 40-6	8.4	17
137	Effect of colesevelam hydrochloride on glycemia and insulin sensitivity in men with the metabolic syndrome. <i>American Journal of Cardiology</i> , 2011 , 108, 1129-35	3	18
136	AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation. <i>Circulation</i> , 2011 , 124, 2458-73	16.7	1087
135	Can we dramatically reduce the incidence of coronary heart disease?. <i>Nature Reviews Cardiology</i> , 2011 , 8, 721-5	14.8	33
134	Genetic variants influencing circulating lipid levels and risk of coronary artery disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2010 , 30, 2264-76	9.4	318
133	Indices of cholesterol metabolism and relative responsiveness to ezetimibe and simvastatin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2010 , 95, 800-9	5.6	61
132	The metabolic syndrome. <i>Lancet, The</i> , 2010 , 375, 181-3	40	720
131	Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. <i>Circulation</i> , 2009 , 120, 1640-5	16.7	8793
130	Sex differences in the relationship between C-reactive protein and body fat. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2009 , 94, 3251-8	5.6	108
129	Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial). <i>American Journal of Cardiology</i> , 2009 , 104, 548-53	3	31
128			

127	Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study). <i>American Journal of Cardiology</i> , 2009 , 103, 1694-702	3	55
126	Ethnic differences in hepatic steatosis: an insulin resistance paradox?. <i>Hepatology</i> , 2009 , 49, 791-801	11.2	252
125	Evaluation of coronary artery calcium screening strategies focused on risk categories: the Dallas Heart Study. <i>American Heart Journal</i> , 2009 , 157, 1001-9	4.9	8
124	Impaired hepatic ketogenesis in moderately obese men with hypertriglyceridemia. <i>Journal of Investigative Medicine</i> , 2009 , 57, 590-4	2.9	6
123	Metabolic syndrome pandemic. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, 629-36	9.4	988
122	Promise of low-density lipoprotein-lowering therapy for primary and secondary prevention. <i>Circulation</i> , 2008 , 117, 569-73; discussion 573	16.7	34
121	A changing paradigm for prevention of cardiovascular disease: emergence of the metabolic syndrome as a multiplex risk factor. <i>Country Review Ukraine</i> , 2008 , 10, B16-B23		15
120	Thyroid mimetic as an option for lowering low-density lipoprotein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008 , 105, 409-10	11.5	4
119	Independent associations between metabolic syndrome, diabetes mellitus and atherosclerosis: observations from the Dallas Heart Study. <i>Diabetes and Vascular Disease Research</i> , 2008 , 5, 96-101	3.3	48
118	Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment. <i>Circulation</i> , 2008 , 117, 3002-9	16.7	357
117	Variable contributions of fat content and distribution to metabolic syndrome risk factors. <i>Metabolic Syndrome and Related Disorders</i> , 2008 , 6, 281-8	2.6	29
116	TNT Trial 2008 , 1		
115	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on	15.1	753
114	The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , 2007 , 50, 752-9	15.1	130
113	Metabolic syndrome: a multiplex cardiovascular risk factor. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2007 , 92, 399-404	5.6	466
112	Insulin resistance and body fat distribution in South Asian men compared to Caucasian men. <i>PLoS ONE</i> , 2007 , 2, e812	3.7	160
111	Reply to AM Zivkovic and JB German. <i>American Journal of Clinical Nutrition</i> , 2007 , 85, 241-242	7	
110	Metabolic correlates of nonalcoholic fatty liver in women and men. <i>Hepatology</i> , 2007 , 46, 716-22	11.2	64

109	Harmonizing the definition of the metabolic syndrome: comparison of the criteria of the Adult Treatment Panel III and the International Diabetes Federation in United States American and European populations. <i>American Journal of Cardiology</i> , 2007 , 99, 541-8	3	114
108	Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007 , 27, 2043-9	9.4	83
107	Metabolic syndrome phenotype in very obese women. <i>Metabolic Syndrome and Related Disorders</i> , 2007 , 5, 3-12	2.6	3
106	Should women be offered cholesterol lowering drugs to prevent cardiovascular disease? Yes. <i>BMJ, The</i> , 2007 , 334, 982	5.9	13
105	ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring by computed tomography in global cardiovascular risk assessment and in evaluation of patients with chest pain: a report of the American College of Cardiology Foundation Clinical Expert Consensus Task Force (ACCF/AHA Writing Committee to Update the 2000 Expert Consensus Document on	16.7	399
104	Relationship of apolipoprotein B levels to the number of risk factors for metabolic syndrome. <i>Journal of Investigative Medicine</i> , 2007 , 55, 237-47	2.9	11
103	Cardiovascular and metabolic risk factors: how can we improve outcomes in the high-risk patient?. <i>American Journal of Medicine</i> , 2007 , 120, S3-8; discussion S9	2.4	30
102	Sex differences in the association between leptin and CRP: results from the Dallas Heart Study. <i>Atherosclerosis</i> , 2007 , 195, 404-10	3.1	56
101	Management of Cholesterol Disorders 2007 , 2667-2691		
100	Non-high-density lipoprotein and very-low-density lipoprotein cholesterol and their risk predictive values in coronary heart disease. <i>American Journal of Cardiology</i> , 2006 , 98, 1363-8	3	215
99	Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. <i>Clinical Cornerstone</i> , 2006 , 8 Suppl 1, S21-7		65
98	Relationship between C-reactive protein and subclinical atherosclerosis: the Dallas Heart Study. <i>Circulation</i> , 2006 , 113, 38-43	16.7	165
97	AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. <i>Circulation</i> , 2006 , 113, 2363-72	16.7	1395
96	Does the metabolic syndrome exist?. <i>Diabetes Care</i> , 2006 , 29, 1689-92; discussion 1693-6	14.6	121
95	Multiple rare variants in NPC1L1 associated with reduced sterol absorption and plasma low-density lipoprotein levels. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006 , 103, 1810-5	11.5	344
94	Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. <i>Diabetes Care</i> , 2006 , 29, 1220-6	14.6	410
93	Influence of body fat content and distribution on variation in metabolic risk. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006 , 91, 4459-66	5.6	226
92	Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. <i>Lancet, The</i> , 2006 , 368, 919-28	40	315

91	Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 1093-100	15.1	441
90	Combination of fenofibrate plus low-dose nicotinic acid added to statin treatment in type 2 diabetes: An open-label, crossover study. <i>Current Therapeutic Research</i> , 2006 , 67, 321-33	2.4	1
89	Does a diagnosis of metabolic syndrome have value in clinical practice?. <i>American Journal of Clinical Nutrition</i> , 2006 , 83, 1248-51	7	123
88	Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy. <i>Nature Reviews Drug Discovery</i> , 2006 , 5, 295-309	64.1	195
87	The metabolic syndrome. <i>Lancet, The</i> , 2005 , 365, 1415-28	40	4380
86	Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. <i>Circulation</i> , 2005 , 112, 2735-52	16.7	8005
85	Joint distribution of non-HDL and LDL cholesterol and coronary heart disease risk prediction among individuals with and without diabetes. <i>Diabetes Care</i> , 2005 , 28, 1916-21	14.6	189
84	Diagnosis and Management of the Metabolic Syndrome. <i>Circulation</i> , 2005 , 112,	16.7	217
83	Intensive lipid lowering with atorvastatin in patients with stable coronary disease. <i>New England Journal of Medicine</i> , 2005 , 352, 1425-35	59.2	2591
82	Relation between atherogenic dyslipidemia and the Adult Treatment Program-III definition of metabolic syndrome (Genetic Epidemiology of Metabolic Syndrome Project). <i>American Journal of Cardiology</i> , 2005 , 95, 194-8	3	60
81	Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial). <i>American Journal of Cardiology</i> , 2005 , 95, 462-8	3	257
80	Stanol esters as a component of maximal dietary therapy in the National Cholesterol Education Program Adult Treatment Panel III report. <i>American Journal of Cardiology</i> , 2005 , 96, 47D-50D	3	48
79	A constellation of complications: the metabolic syndrome. <i>Clinical Cornerstone</i> , 2005 , 7, 36-45		48
78	Point: the metabolic syndrome still lives. <i>Clinical Chemistry</i> , 2005 , 51, 1352-4	5.5	51
77	Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?. <i>Circulation</i> , 2004 , 109, 2818-25	16.7	508
76	Adipose tissue metabolites and insulin resistance in nondiabetic Asian Indian men. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2750-5	5.6	141
75	No association between plasma levels of plant sterols and atherosclerosis in mice and men. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 2326-32	9.4	146
74	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. <i>Circulation</i> , 2004 , 110, 227-39	16.7	4450

73	Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, e13-8	9.4	538
72	Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. <i>Diabetes Care</i> , 2004 , 27, 256-63	14.6	479
71	Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. <i>Hepatology</i> , 2004 , 40, 1387-95	11.2	2757
70	What is the contribution of obesity to the metabolic syndrome?. <i>Endocrinology and Metabolism Clinics of North America</i> , 2004 , 33, 267-82, table of contents	5.5	54
69	African Americans and Caucasians have a similar prevalence of coronary calcium in the Dallas Heart Study. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 1011-7	15.1	158
68	Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. <i>Circulation</i> , 2004 , 109, 433-8	16.7	3857
67	Obesity, metabolic syndrome, and cardiovascular disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004 , 89, 2595-600	5.6	872
66	Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. <i>Journal of the American College of Cardiology</i> , 2004 , 44, 720-32	15.1	1070
65	Elevated plasma high-sensitivity C-reactive protein concentrations in Asian Indians living in the United States. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 3773-6	5.6	92
64	The metabolic syndrome: a practical guide to origins and treatment: Part II. <i>Circulation</i> , 2003 , 108, 1537-40	4.7	68
63	Efficacy and Safety of Plant Stanols and Sterols in the Management of Blood Cholesterol Levels. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 965-978	6.4	759
62	Metabolic syndrome: what is it and how should I treat it?. <i>ACC Current Journal Review</i> , 2003 , 12, 37-40		2
61	Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. <i>American Journal of Cardiology</i> , 2003 , 91, 956-60	3	145
60	Atherosclerosis imaging for risk assessment and primary prevention of cardiovascular disease. <i>Progress in Cardiovascular Diseases</i> , 2003 , 46, 115-21	8.5	7
59	Efficacy and safety of plant stanols and sterols in the management of blood cholesterol levels. <i>Mayo Clinic Proceedings</i> , 2003 , 78, 965-78	6.4	297
58	Genetic polymorphism PC-1 K121Q and ethnic susceptibility to insulin resistance. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 5927-34	5.6	100
57	Approach to lipoprotein management in 2001 National Cholesterol Guidelines. <i>American Journal of Cardiology</i> , 2002 , 90, 11i-21i	3	251
56	Alternative approaches to cholesterol-lowering therapy. <i>American Journal of Cardiology</i> , 2002 , 90, 1135-8		7

55	Statin therapy in older persons: pertinent issues. <i>Archives of Internal Medicine</i> , 2002 , 162, 1329-31		21
54	Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. <i>Archives of Internal Medicine</i> , 2002 , 162, 1568-76		432
53	Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. <i>Circulation</i> , 2002 , 106, 2526-9	16.7	230
52	ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. <i>Circulation</i> , 2002 , 106, 1024-8	16.7	410
51	AHA Guidelines for Primary Prevention of Cardiovascular Disease and Stroke: 2002 Update: Consensus Panel Guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. <i>Circulation</i> , 2002 , 106, 388-91	16.7	1349
50	Diet composition and the metabolic syndrome: what is the optimal fat intake?. <i>American Journal of Medicine</i> , 2002 , 113 Suppl 9B, 25S-29S	2.4	100
49	ACC/AHA/NHLBI clinical advisory on the use and safety of statins. <i>Journal of the American College of Cardiology</i> , 2002 , 40, 567-72	15.1	504
48	Coronary plaque as a replacement for age as a risk factor in global risk assessment. <i>American Journal of Cardiology</i> , 2001 , 88, 8E-11E	3	77
47	United States Cholesterol Guidelines 2001: expanded scope of intensive low-density lipoprotein-lowering therapy. <i>American Journal of Cardiology</i> , 2001 , 88, 23J-27J	3	84
46	AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Circulation</i> , 2001 , 104, 1577-9	16.7	464
45	Validation of the Framingham coronary heart disease prediction scores: results of a multiple ethnic groups investigation. <i>JAMA - Journal of the American Medical Association</i> , 2001 , 286, 180-7	27.4	1429
44	AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 update. A statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 2001 , 38, 1501-8	15.1	210
43	Non-high-density lipoprotein cholesterol level as potential risk predictor and therapy target. <i>Archives of Internal Medicine</i> , 2001 , 161, 1379-80		30
42	Dietary fat: at the heart of the matter. <i>Science</i> , 2001 , 293, 801-4	33.3	16
41	Metabolic complications of obesity. <i>Endocrine</i> , 2000 , 13, 155-65		139
40	American College of Cardiology/American Heart Association Expert Consensus document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. <i>Circulation</i> , 2000 , 102, 126-40	16.7	565
39	American College of Cardiology/American Heart Association Expert Consensus Document on electron-beam computed tomography for the diagnosis and prognosis of coronary artery disease. <i>Journal of the American College of Cardiology</i> , 2000 , 36, 326-40	15.1	276
38	Primary prevention of coronary heart disease: integrating risk assessment with intervention. <i>Circulation</i> , 1999 , 100, 988-98	16.7	164

37	Hepatic lipase (LIPC) promoter polymorphism in men with coronary artery disease. Allele frequency and effects on hepatic lipase activity and plasma HDL-C concentrations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1999 , 19, 1975-8	9.4	48
36	Diabetes and cardiovascular disease: a statement for healthcare professionals from the American Heart Association. <i>Circulation</i> , 1999 , 100, 1134-46	16.7	1470
35	AHA/ACC scientific statement: Assessment of cardiovascular risk by use of multiple-risk-factor assessment equations: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. <i>Journal of the American College of Cardiology</i> , 1999 , 34, 1348-59	15.1	319
34	Hypertriglyceridemia, atherogenic dyslipidemia, and the metabolic syndrome. <i>American Journal of Cardiology</i> , 1998 , 81, 18B-25B	3	378
33	Statin trials and goals of cholesterol-lowering therapy. <i>Circulation</i> , 1998 , 97, 1436-9	16.7	156
32	Cholesterol management in high-risk patients without heart disease. When is lipid-lowering medication warranted for primary prevention?. <i>Postgraduate Medicine</i> , 1998 , 104, 117-20, 123-4, 129	3.7	4
31	Three polymorphisms associated with low hepatic lipase activity are common in African Americans. <i>Journal of Lipid Research</i> , 1998 , 39, 1900-1903	6.3	25
30	Body mass index and hepatic lipase gene (LIPC) polymorphism jointly influence postheparin plasma hepatic lipase activity. <i>Journal of Lipid Research</i> , 1998 , 39, 1127-1130	6.3	46
29	Hepatic lipase activity is lower in African American men than in white American men: effects of 5' flanking polymorphism in the hepatic lipase gene (LIPC). <i>Journal of Lipid Research</i> , 1998 , 39, 228-232	6.3	121
28	Relationship of anterior and posterior subcutaneous abdominal fat to insulin sensitivity in nondiabetic men. <i>Obesity</i> , 1997 , 5, 93-9		154
27	Cholesterol management in patients with heart disease. Emphasizing secondary prevention to increase longevity. <i>Postgraduate Medicine</i> , 1997 , 102, 81-4, 87-90	3.7	7
26	Small LDL, atherogenic dyslipidemia, and the metabolic syndrome. <i>Circulation</i> , 1997 , 95, 1-4	16.7	217
25	Hypoalphalipoproteinemia (low high density lipoprotein) as a risk factor for coronary heart disease. <i>Current Opinion in Lipidology</i> , 1996 , 7, 209-16	4.4	59
24	Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). <i>JAMA - Journal of the American Medical Association</i> , 1993 , 269, 3015	27.4	1589
23	Reply to ML Goldberg and MG Enig. <i>American Journal of Clinical Nutrition</i> , 1993 , 58, 244-244	7	
22	Oxidized LDL and atherogenesis: relation to risk factors for coronary heart disease. <i>Clinical Cardiology</i> , 1993 , 16, 13-5	3.3	20
21	Recent nutrition research: implications for foods of the future. <i>Annals of Medicine</i> , 1991 , 23, 187-93	1.5	15
20	Drug Therapy in Dyslipidemia. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990 , 50, 63-72	2	1

19	Cholesterol and coronary heart disease. <i>Scandinavian Journal of Clinical and Laboratory Investigation</i> , 1990 , 199, 17-24	2	2
18	Treatment of diabetic dyslipidaemia. <i>Biochemical Society Transactions</i> , 1989 , 17, 56-8	5.1	2
17	Comparison of the effects of guanabenz and hydrochlorothiazide on plasma lipids. <i>Clinical Pharmacology and Therapeutics</i> , 1988 , 44, 297-302	6.1	4
16	Lovastatin therapy in receptor-negative homozygous familial hypercholesterolemia: lack of effect on low-density lipoprotein concentrations or turnover. <i>Journal of Pediatrics</i> , 1988 , 113, 387-92	3.6	72
15	HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. <i>New England Journal of Medicine</i> , 1988 , 319, 24-33	59.2	663
14	Fibric acids: effects on lipids and lipoprotein metabolism. <i>American Journal of Medicine</i> , 1987 , 83, 9-20	2.4	175
13	Accumulation of 7 alpha-hydroxy-4-cholesten-3-one and cholesta-4,6-dien-3-one in patients with cerebrotendinous xanthomatosis: effect of treatment with chenodeoxycholic acid. <i>Hepatology</i> , 1987 , 7, 266-71	11.2	44
12	Cholesterol and Coronary Heart Disease. <i>JAMA - Journal of the American Medical Association</i> , 1986 , 256, 2849	27.4	237
11	Comparison of monounsaturated fatty acids and carbohydrates for lowering plasma cholesterol. <i>New England Journal of Medicine</i> , 1986 , 314, 745-8	59.2	605
10	Effects of AOMA on cholesterol metabolism in man. <i>Metabolism: Clinical and Experimental</i> , 1982 , 31, 733-9	12.7	26
9	The possible role of the arterial microcirculation in the pathogenesis of atherosclerosis. <i>Journal of Chronic Diseases</i> , 1980 , 33, 679-84		37
8	Effects of sucrose polyester on cholesterol metabolism in man. <i>Metabolism: Clinical and Experimental</i> , 1979 , 28, 994-1000	12.7	75
7	Transport of very low density lipoprotein triglycerides in varying degrees of obesity and hypertriglyceridemia. <i>Journal of Clinical Investigation</i> , 1979 , 63, 1274-83	15.9	226
6	Plant sterols as cholesterol-lowering agents: clinical trials in patients with hypercholesterolemia and studies of sterol balance. <i>Atherosclerosis</i> , 1977 , 28, 325-38	3.1	282
5	Chylomicron clearance in normal and hyperlipidemic man. <i>Metabolism: Clinical and Experimental</i> , 1976 , 25, 1225-39	12.7	194
4	A Physiological Method for Estimation of Hepatic Secretion of Biliary Lipids in Man. <i>Gastroenterology</i> , 1972 , 62, 1200-1217	13.3	211
3	Mechanisms of action of clofibrate on cholesterol metabolism in patients with hyperlipidemia. <i>Journal of Lipid Research</i> , 1972 , 13, 531-551	6.3	215
2	Dietary β -sitosterol as an internal standard to correct for cholesterol losses in sterol balance studies. <i>Journal of Lipid Research</i> , 1968 , 9, 374-387	6.3	173

- 1 Cholesterol Management in the Context of Risk Factor Profile 187-195